Drug Search Results

Pemrametostat

Alternative Names: Pemrametostat, gsk-3326595, gsk3326595, gsk 3326595
Latest Update: 2024-03-13
Latest Update Note: PubMed Publication

Product Description

For relapsed and refractory MDS, chronic myelomonocytic leukemia (CMML), and AML (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03614728)

Mechanisms of Action: PRMT5 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pemrametostat

Countries in Clinic: Canada, France, Netherlands, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Breast Cancer

Phase 1: Lymphoma, Non-Hodgkin

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
Meteor 1	P1	Completed	Lymphoma, Non-Hodgkin	2023-08-30	43%
OTT-19-06	P2	Completed	Breast Cancer	2022-08-15

Recent News Events

Date	Type	Title
03/13/2024	PubMed	PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
01/01/2024	PubMed	Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
11/02/2023	PubMed	PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma.
01/17/2022	News Article	Global Acute Myeloid Leukaemia Pipeline Landscape Report 2021 - Comprehensive Insights for Approx 150+ Companies and 150+ Pipeline Drugs - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions